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Background: Pharmacogenomic profiling is an attractive strategy
for individualizing chemotherapy. Several genetic polymorphisms
predict the survival of patients with non-small cell lung cancer
treated with platinum-based chemotherapy. This phase II clinical
trial was performed using a non–platinum-based chemotherapy
doublet. The impact of previously identified polymorphisms on
clinical outcomes was assessed.
Methods: Patients with advanced non-small cell lung cancer who
had not received previous chemotherapy were treated with docetaxel
40 mg/m2 on days 1 and 8 and gemcitabine 800 mg/m2 days 1 and
8 every 21 days until disease progression or unacceptable toxicity. A
pretreatment blood sample was obtained, and genomic DNA was
analyzed for polymorphisms in DNA repair and metabolic genes.
Results: Forty-nine patients were enrolled and evaluated for response
and survival. The overall radiographic response rate was 38%, and the
median survival was 8.6 months. Nonhematologic toxicity was gener-
ally mild. Two treatment related deaths occurred: one due to neutro-
penic sepsis during the first cycle and one due to pulmonary edema after
12 cycles of treatment. Polymorphisms in XPD, XRCC1, and XRCC3
did not significantly predict survival, but trends similar to those reported
for platinum-based chemotherapy were observed. The wild-type XPD
genotype was associated with prolonged survival and a significantly
higher risk of grade 4 neutropenia (p  0.02).
Conclusion: This regimen of docetaxel and gemcitabine is well toler-
ated and active for the treatment of advanced non-small cell lung
cancer. The impact of XPD polymorphisms on hematologic toxicity is
similar to what has been reported for platinum-based chemotherapy.
Key Words: Pharmacogenomics, Lung cancer, Docetaxel, Gem-
citabine.
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Non-small cell lung cancers vary in biological aggressive-ness and chemotherapy sensitivity. When administered
to an unselected population, several chemotherapy regimens
produce similar improvements in survival.1–5 Individualizing
chemotherapy is an attractive strategy for improving out-
comes.6 Polymorphisms in DNA repair genes alter chemo-
therapy sensitivity and can be measured using peripheral
blood, making them attractive for clinical testing.6–11
Options for frontline chemotherapy include platinum-
based and non–platinum-based chemotherapy doublets.12
Non–platinum-based chemotherapy doublets, including do-
cetaxel and gemcitabine, have demonstrated similar survival
benefits compared with platinum-based doublets in random-
ized phase III clinical trials.4,5 These combinations represent
a reasonable option for frontline treatment but are generally
reserved for patients with contraindications to platinum such
as renal insufficiency.
Polymorphisms in certain DNA repair genes including
XPD, XRCC1, and XRCC3 have been reported to predict the
survival of patients treated with platinum-based chemother-
apy.7–11 These polymorphisms may be useful markers of
resistance to platinum-containing regimens. However, it is
also possible that these polymorphisms predict biological
aggressiveness independent of the treatment administered.
The current phase II clinical trial was performed to assess
the safety and activity of a non–platinum-based chemotherapy
doublet, gemcitabine, and docetaxel. Polymorphisms in XPD,
XRCC1, XRCC3, and other genes were assessed to determine
whether these would predict clinical outcomes for this non–
platinum-based chemotherapy regimen.
MATERIALS AND METHODS
Patient Eligibility
Patients were required to have stage IIIB with malig-
nant effusion or stage IV non-small cell lung cancer. Patients
who had relapsed after initial surgery or radiation therapy
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were eligible provided they had not received previous che-
motherapy. Patients with brain metastases were eligible 2
weeks after completing radiation therapy. All patients were
required to have a documented histopathologic or cytopatho-
logic diagnosis. Patients were also required to have measur-
able disease and Eastern Cooperative Oncology Group per-
formance status of 0 or 1. Patients were ineligible if they had
received previous chemotherapy, had inadequate organ func-
tion, were pregnant or breast-feeding, or were currently
receiving radiation therapy. Adequate organ function was
defined as absolute neutrophil count 1500/L; platelet
count 100,000/l; creatinine two times or less the upper
limit of normal (ULN); normal bilirubin; and adequate liver
enzyme levels, which were defined as aspartate aminotrans-
ferase (AST) and alanine aminotransferase (ALT) 2.5 times
or less the ULN with a normal alkaline phosphatase; alkaline
phosphatase four times or less the ULN with normal AST and
ALT; or AST and ALT 1.5 times or less the ULN and
alkaline phosphatase 2.5 times of less the ULN.
Study Design
This study was approved by the Institutional Review
Board of Wake Forest University and the Protocol Review
Committee of the Comprehensive Cancer Center of Wake
Forest University. After obtaining written informed consent,
patients were treated with gemcitabine 800 mg/m2 followed
by docetaxel 40 mg/m2 with both drugs given intravenously
on days 1 and 8 every 3 weeks. This dose and schedule were
selected based on results of a phase I clinical trial that found
this regimen to be well tolerated and active.13 Treatment was
continued until unacceptable toxicity or disease progression.
Gemcitabine was mixed in 250 ml of normal saline and
administered over 30 minutes. Docetaxel was mixed in an
appropriate volume of normal saline or D5W and adminis-
tered over 30 minutes immediately after gemcitabine. Re-
quired premedication consisted of dexamethasone 8 mg
orally 12 hours before, 1 hour before, and 12 hours after
docetaxel administration. Optional premedications included
5-HT3 antagonists, diphenhydramine, and H2 blockers. Pro-
phylactic granulocyte growth factor support was not admin-
istered with the first cycle but could be given with subsequent
cycles.
Toxicity and Response Assessment
Physical examination and routine laboratory tests were
performed before each cycle of chemotherapy. Complete
blood counts were performed weekly for the first two cycles
and then before each treatment for the remaining cycles.
National Cancer Institute Common Toxicity Criteria version
2.0 was used for grading toxicity. Doses were reduced by
25% for febrile neutropenia, grade 4 neutropenia for7 days,
or platelet count 100,000. Docetaxel doses were held for
abnormal liver function with total bilirubin more than the
ULN, alkaline phosphatase more than five times the ULN, or
AST more than five times the ULN. Doses were held for
nonhematologic toxicities grade 3 or higher with doses re-
started once toxicity improved to grade 2. In the case of
pulmonary toxicity grade 3 or higher or anaphylaxis, treat-
ment was permanently discontinued.
Tumor measurements were performed before initiation
of treatment and then every two cycles until disease progres-
sion or unacceptable toxicity. Tumor response was assessed
using Response Evaluation Criteria in Solid Tumors.14
Genotyping Procedure
Blood samples were obtained before treatment. DNA was
extracted from the samples using Qiagen’s QiAampDNABlood
Mini Kit (Valencia, CA). Gene polymorphisms in drug meta-
bolic and DNA repair enzymes were determined by polymerase
chain reaction–restriction fragment length polymorphism
(CYP1A1,15 CYP3A5,16 GSTP1 105, XRCC1,17 XRCC3,17 and
XPD) or polymerase chain reaction–single-stranded conforma-
tional polymorphism (GSTP1 114) using the primers and con-
ditions listed in Table 1. Standard PCR conditions for all genes
were as follows: initial denaturation at 95°C followed by 40
cycles of denaturation at 95°C for 30 seconds, extension at 72°C
for 1 minute, and a final extension at 72°C for 7 minutes.
Specific annealing temperatures and times as well as restriction
digestion enzymes are listed in Table 1. The numbering of
CYP1A1 base pair changes listed in Table 1 has been updated in
accordance with currently accepted nomenclature.
For determination of GSTP1 114 variants, DNA was
amplified and analyzed by SSCP using Amersham’s Gene-
Phor System. Precast GeneGel Clean 15/24 acrylamide gel
was rehydrated in Buffer B according to the manufacturer’s
instructions and polymerase chain reaction product was de-
natured at 95°C for 5 minutes in a 99% formamide buffer
containing 0.04% bromophenol blue and 0.05% xylene cya-
nol and then immediately placed on ice. Six microliters of the
sample was loaded onto the gel and electrophoresed at 13°C
for 15 minutes at 170 V, 10 mA, 5 W, then 45 minutes at 310
V, 15 mA, 5 W, and finally 15 minutes at 380 V, 15 mA, 5
W. The wild-type and variant alleles were distinguishable
through the specific banding patterns observed on the gel
after staining with the Plus One DNA Silver Staining Kit
(Amersham BioSciences, Piscataway, NJ.).
Statistical Methods
The sample size was selected based on having 90%
power to demonstrate a 20% improvement in an expected
response rate of 30% using a two-stage Simon design. The
first stage was designed to include 22 patients with the study
being stopped and the null hypothesis accepted if seven or
fewer patients responded to therapy. Survival, progression-
free survival, and toxicity statistics were performed on an
intent-to-treat basis. Survival and time to progression were
assessed using the Kaplan-Meier method. Comparisons of
survival curves were performed using the log-rank test. Cor-
relations of genotype with clinical outcomes were performed
using the Fisher exact test. All p values shown are two sided.
Statistical significance was defined as a two-sided p value
0.05.
RESULTS
Patients
Forty-nine patients were enrolled. After enrollment,
one patient was found to be ineligible due to performance
Petty et al. Journal of Thoracic Oncology • Volume 2, Number 3, March 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer198
status of 2. The patient characteristics are displayed in Table
2. The majority of the patients had Eastern Cooperative
Oncology Group performance status of 1 and stage IV dis-
ease. Other patient demographics were within the expected
range for a population of patients with advanced non-small
cell lung cancer.
Response and Survival
At the time of analysis, the median duration of fol-
low-up was 262 days. The median survival was 8.6 months
and the median progression-free survival was 4.0 months,
displayed in Figure 1. The 1- and 3-year survival probabilities
were 37% and 18%, respectively.
Four patients were not assessable for radiographic re-
sponse. One patient was ineligible due to performance status,
and three patients died without evidence of progression be-
fore completing two cycles. One died of neutropenic sepsis
due to treatment, one died of a pulmonary embolism due to
cancer, and one died of a probable intracerebral hemorrhage
due to cancer.
Of the 45 patients assessable for radiographic response,
changes in tumor measurements were partial response in 17
(38%), stable disease in 17 (38%), and progressive disease in
11 (24%). This did not meet the predefined endpoint of a
greater than 39% response rate.
Toxicity
All patients were assessable for toxicity. Nonhemato-
logic toxicity was generally mild. Grade 3 and 4 nonhema-
tologic toxicities considered at least possibly related to treat-
ment are displayed in Table 3. Two treatment-related deaths
occurred. One patient died of neutropenic sepsis during the
first cycle of treatment. Another patient died of progressive
pulmonary edema after receiving 12 cycles of treatment.
Hematologic toxicity is summarized in Table 4. Grade
3 or 4 hematologic toxicity occurred in 24 (49%) patients.
Grade 4 neutropenia occurred in seven (14%) patients. Fe-
brile neutropenia occurred in only one patient who subse-
quently died of neutropenic sepsis.
TABLE 1. PCR Primers and Restriction Endonucleases for PCR-Restriction Fragment Length Polymorphism Analyses
Gene (amino acid or base change) PCR Primers Anneal Temp (C) (time) Restriction Digest
CYP1A1 (T3801C and T3205C) 5= Primer 5=- TAGGAGTCTTGTCTCATGCCT-3=
3= Primer 5=-GGCTGAGCAATCTGACCCTA-3=
63° (60s) MspI
CYP1A1 (I462V) 5= Primer 5=-CTGTCTCCCTCTGGTTACAGGAAGC-3=
3= Primer 5=-TTCCACCCGTTGCAGCAGGATAGCC-3=
63° (60s) BsrDI
CYP3A5*3 (A6986G) 5= Primer 5=-CTTTAAAGAGCTCTTTTGTCTCTCA-3=
3= Primer 5=-CCAGGAAGCCAGACTTGAT-3=
56° (30s) DdeI
CYP3A5*6 (G14690A) 5= Primer 5=-GTGGGTTTCTTGCTGCATGT-3=
3= Primer 5=-GCCCACATACTTATTGAGAG-3=
58° (30s) DdeI
GSTP1 (I105V) 5= Primer 5=-AACCCCAGGGCTCTATGGG-3=
3= Primer 5=-GAAGCCCCTTTCTTTGTT-3=
55° (60s) BsmBI
GSTP1 (A114V) 5= Primer 5=-GAGAGTAGGATGATACATGG-3=
3= Primer 5=-GGAACAGCATGGGGCCAGATG-3=
55° (60s) N/A
XRCCI (R194W) 5= Primer 5=-GCCCCGTCCCAGGTA-3=
3= Primer 5=-AGCCCCAAGACCCTTTCACT-3=
57° (90s) PvuII
XRCCI (R399Q) 5= Primer 5=-TCTCCCTTGGTCTCCAACCT-3=
3= Primer 5=-AGTAGTCTGCTGGCTCTGG-3=
57° (90s) MspI
XRCC3 (T241M) 5= Primer 5=-GGTCGAGTGACAGTCCAAAC-3=
3= Primer 5=-TGCAACGGCTGAGGGTCTT-3=
57° (90s) NlaIII
XPD (K751Q) 5= Primer 5=-CATCTTATGTTGACAGGGATG-3=
3= Primer 5=-CTGCGATTAAAGGCTGTGGA-3=
57° (90s) EarI
PCR, polymerase chain reaction. PCR-restriction fragment length polymorphism analysis for CYP1A1,14, CYP3A5,15, XRCC1,16, and XRCC316 polymorphisms were performed
as described previously.
TABLE 2. Patient Characteristics
No. (%)
Median age (range) 64 (40–79)
Sex
Male 31 (63)
Female 18 (37)
Race
White 41 (84)
Black 8 (16)
ECOG Performance Status
0 19 (39)
1 29 (59)
2 1 (2)
Stage
IIIB 1 (2)
IV 48 (98)
Histology
Adenocarcinoma 25 (51)
Bronchioloalveolar 1 (2)
Squamous cell 13 (27)
Large cell 1 (2)
Other 9 (18)
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Dose Intensity
The planned dose intensity was 27 mg/m2 per week for
docetaxel and 533 mg/m2 per week for gemcitabine. Eight
patients (16%) required a dose reduction during the course of
therapy. The percentage of the total planned chemotherapy
dose actually delivered to patients was 97%.
Pharmacogenomic Analyses
Genotyping was performed on blood samples obtained
from 36 patients who were assessable for survival and tox-
icity. Thirty-three were also assessable for response. Toxici-
ties were examined and compared for patients with wild-type
genotype or harboring one or two variant alleles (Table 5).
Neutropenia was more severe in patients with a wild-type
XPD genotype. Grade 4 neutropenia occurred in five of 13
(38%) wild-type cases and only one of 23 (4%) variant cases
(p  0.02).
None of the examined polymorphisms significantly
correlated with response rate or median survival. Polymor-
phisms in XPD, XRCC1 399, and XRCC3 had previously
been reported to predict survival for patients treated with
platinum-based chemotherapy. Although the median survival
values were not significantly different, 2-year survival trends
similar to those observed for platinum-based chemotherapy
were observed for XPD, XRCC1 399, and XRCC3. The
2-year survival probability for all patients was 18%. Patients
with a homozygous variant XPD or XRCC1 399 genotype
tended to have a shorter survival with none of these patients
alive at 2 years compared with a 2-year survival of 22% (95%
confidence interval [CI]: 11%–43%) for patients with at least
one wild-type XPD allele and 23% (95% CI, 11%–47%) for
patients with at least one wild-type XRCC1 399 allele.
Patients with a homozygous variant XRCC3 genotype tended
to have a longer survival with 50% (95% CI: 22%–100%) of
patients harboring this genotype alive at 2 years compared
with a 2-year survival of 13% (95% CI: 5%–33%) for patients
with at least one wild-type XRCC3 allele.
DISCUSSION
Cytotoxic chemotherapy continues to be the mainstay
for initial treatment of patients with advanced non-small cell
lung cancer. Individualizing chemotherapy to deliver the
most active agent to each patient could provide an important
advance.6 Previous studies have identified pharmacogenomic
predictors of survival for patients with advanced non-small
cell lung cancer treated with platinum-based chemotherapy.7–11
Among these are the XRCC1, XRCC3, and XPD genes. Each
of these genes plays an important role in the repair of DNA
damage.18–25
Similar to previous studies of platinum-based che-
motherapy, we identified a trend toward decreased survival
for patients with variant XPD or XRCC1 genotype and
FIGURE 1. Overall (A) and progression-free (B) survival.
TABLE 3. Treatment-Related Nonhematologic Toxicity
Toxicity
Grade
3 (%)
Grade
4 (%)
Grade
5 (%)
Total
(%)
Hypersensitivity 2 0 0 2
Anorexia 2 0 0 2
Diarrhea 10 0 0 10
Fatigue 4 0 0 4
Hyperglycemia 8 0 0 8
Infection 6 0 2 8
Nausea/vomiting 6 0 0 6
Neuropathy 2 0 0 2
Hepatic 2 0 0 2
Weight loss 2 0 0 4
Mucositis 4 0 0 4
Pulmonary edema 0 0 2 2
TABLE 4. Hematologic Toxicity
Toxicity
Grade 3
(%)
Grade 4
(%)
Total
(%)
Neutropenia 18 14 33
Leukocytopenia 18 6 25
Anemia 4 0 4
Thrombocytopenia 12 0 12
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increased survival for patients with variant XRCC3 geno-
type. Based on these findings, it is not clear that these three
polymorphisms will prove useful for choosing between
platinum- or non–platinum-based combination chemother-
apy for initial treatment.
Our findings suggest that the XPD variant genotype
confers resistance to this nonplatinum chemotherapy in the
bone marrow and the tumor. Patients with homozygous
variant XPD genotype experienced both poorer survival and
a lower rate of neutropenia. These two effects of XPD
polymorphisms have been observed in previous studies using
platinum-based chemotherapy.7–9,11 Finding differences in
neutropenia indicate that XPD polymorphisms alter chemo-
therapy sensitivity and do not simply mark the biological
aggressiveness of the tumor.
Determining how XPD polymorphisms confer resis-
tance to cytotoxic chemotherapy could provide an important
advance.21–23,25 XPD is one of nine subunits in the general
transcription factor TIIF. XPD has dual functions in the cell:
nucleotide excision repair and cell cycle regulation through
regulation of Cdk-activating kinase.25,26 Perhaps by under-
standing how XPD functions, new agents targeting XPD
could be developed to overcome chemotherapy resistance. It
is also possible that targeted agents, alone or in combination,
will play a particularly important role for the treatment of the
population of patients harboring a variant XPD genotype.27,28
In the current study, we used peripheral blood to assess
the germ line genotype but did not directly genotype tumor
tissue. It is possible that deletions of one allele could occur
during lung carcinogenesis and render cancers functionally
homozygous despite arising from a heterozygous germ line
population. If so, tumor tissue genotyping could enhance the
predictive value of these polymorphisms. This question
should be studied in future work.
Non–platinum-based chemotherapy doublets combin-
ing several agents including docetaxel, gemcitabine, pacli-
taxel, vinorelbine, and irinotecan at various doses and sched-
ules have been reported.4,5,29–34 The dose and schedule of
docetaxel and gemcitabine used in this study are associated
with an acceptable rate of toxicity and a median survival
within the expected range. This regimen is a reasonable
option for the treatment of patients with advanced non-small
cell lung cancer, particularly those with contraindications to
platinum-based chemotherapy.
A similar dose and schedule of gemcitabine (1000
mg/m2 days 1 and 8) and docetaxel (40 mg/m2 days 1 and 8)
is currently being tested in a randomized phase III clinical
trial led by investigators at Dartmouth and compared with the
combination of carboplatin and docetaxel.5 This study is
powered to show equivalence between the platinum and
non–platinum-based chemotherapy doublets. Preliminary re-
ports indicate that the survival is similar between these
doublets but that differences in the toxicity profiles exist.5
Non–platinum-based chemotherapy produces similar
outcomes to platinum-based chemotherapy. Rational applica-
tion of specific chemotherapy doublets to specific patients
may eventually provide an important advance. The current
study does not provide definite evidence of pharmacog-
enomic profiling using the examined polymorphisms to select
patients for non–platinum-based chemotherapy. Although the
findings of this study are limited by the sample size, it
appears that additional pharmacogenomic markers may need
to be identified for helping clinicians choose between first-
line use of platinum or non-platinum doublets.
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